The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

Although Novo was first to market with Wegovy and its sister ... The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027.

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

RHHBY unveiled plans to invest over $700 million in a new 700,000-square-foot, state-of-the-art drug manufacturing facility ...

Major benchmarks are down this year amid concerns about import tariffs and their impact on economic growth. The stock market may not seem like the ... evaluating the safety and efficacy of Zepbound ...

Those projections include the impact of tariffs as of May 1, but since that situation might change, there's some uncertainty. Despite the factors that led to its post-earnings decline, Eli Lilly ...

The U.S. and China, after trade talks in Geneva, agreed to cut tariffs on each other by 115 percentage points, for at least 90 days. Treasury Secretary Scott Bessent further added that talks on ...